Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing differentiated products using its proprietary PharmFilm drug delivery technology. The company markets Sympazan (clobazam) for Lennox-Gastaut syndrome seizures and Suboxone (buprenorphine/naloxone) film for opioid dependence, while advancing a pipeline including Libervant (diazepam buccal film) for acute repetitive seizures and Anaphylm (epinephrine) for severe allergic reactions. The stock trades on clinical trial outcomes, FDA approval milestones, and commercial execution of its limited product portfolio.
Aquestive generates revenue through direct commercialization of FDA-approved specialty pharmaceuticals using its proprietary buccal film delivery system, which offers advantages over traditional oral tablets including faster absorption, ease of administration for pediatric/geriatric patients, and improved bioavailability. The company's 69% gross margin reflects the specialty nature of its products and limited manufacturing competition for film-based delivery. Pricing power derives from addressing unmet needs in epilepsy and addiction medicine where alternative delivery methods provide clinical differentiation. The company also monetizes its PharmFilm platform through licensing agreements with pharmaceutical partners seeking differentiated formulations of existing molecules.
FDA approval decisions and regulatory milestone announcements for Libervant (diazepam) and Anaphylm (epinephrine), which represent significant revenue expansion opportunities
Quarterly prescription volume trends (TRx data) for Sympazan and Suboxone film indicating commercial traction and market share gains
Clinical trial data readouts and partnership announcements for pipeline candidates using PharmFilm technology
Cash runway updates and financing announcements given negative operating cash flow and need for capital to fund commercialization
Competitive developments in opioid use disorder treatments and epilepsy therapies that could impact market positioning
FDA regulatory approval risk for pipeline candidates Libervant and Anaphylm, where rejection or delayed approval would eliminate near-term revenue growth catalysts and potentially require additional costly trials
Patent expiration and generic competition risk for Suboxone film formulation, which could face biosimilar or generic film competitors eroding pricing power and market share
Healthcare reform and drug pricing legislation risk, particularly for addiction medicine products where government payers represent significant portion of volume and face political pressure on reimbursement rates
Competition from established epilepsy treatments including generic oral formulations and alternative rescue seizure medications (nasal sprays, auto-injectors) that may be preferred by prescribers or payers despite delivery method differences
Opioid use disorder treatment market competition from long-acting injectable formulations (Sublocade, Vivitrol) and implantable options (Probuphine) that offer compliance advantages over daily film administration
Limited commercial infrastructure and sales force scale compared to large pharmaceutical competitors marketing in neurology and addiction medicine, constraining market penetration ability
Severe liquidity risk indicated by negative operating cash flow of $20M+ annually, negative equity position, and limited cash runway requiring near-term financing that could be highly dilutive to existing shareholders
Going concern risk if unable to secure additional financing or achieve profitability before cash depletion, with current burn rate suggesting 12-18 month runway based on typical biotech cash consumption patterns
Negative book value and distressed Debt/Equity ratio of -31.36 indicates accumulated losses exceed assets, creating potential covenant violations or limiting financing options to dilutive equity raises
low - Pharmaceutical demand for epilepsy and opioid addiction treatment is largely non-discretionary and driven by medical necessity rather than economic conditions. However, patient access can be indirectly affected during recessions through insurance coverage changes or Medicaid enrollment shifts. The company's focus on specialty neurological and addiction medicine creates relatively stable demand independent of GDP fluctuations.
Rising interest rates negatively impact Aquestive through multiple channels: (1) higher cost of capital for future financing rounds needed to fund operations given negative cash flow, (2) increased discount rates compress valuation multiples for pre-profitable biotech companies with long-dated cash flows, and (3) reduced risk appetite among growth investors shifts capital away from speculative healthcare names. The company's negative operating cash flow makes it dependent on capital markets access, creating direct financing cost sensitivity.
Moderate credit sensitivity exists through two channels: (1) tightening credit conditions reduce availability and increase cost of capital for equity/debt financing needed to fund operations, and (2) deteriorating credit conditions can pressure payer mix as patients shift between commercial insurance and government programs (Medicaid), affecting net realized pricing. The company's negative Debt/Equity ratio of -31.36 indicates negative equity, making future financing terms highly sensitive to credit market conditions.
growth - The stock attracts speculative growth investors and biotech specialists focused on binary FDA approval catalysts and pipeline value inflection points. The negative profitability, high revenue growth (13.8% YoY), and significant recent volatility (34.3% decline over 3 months) indicate momentum-driven trading around regulatory milestones. Not suitable for value or income investors given negative earnings, no dividend, and distressed balance sheet. Typical holders include biotech-focused hedge funds, retail speculators, and venture-stage healthcare investors willing to accept binary risk/reward profiles.
high - The stock exhibits extreme volatility as evidenced by 34.3% decline in 3 months followed by 26.4% gain over 1 year, typical of small-cap pre-profitable biotech companies. Volatility drivers include binary FDA decision outcomes, clinical trial data releases, financing announcements, and low float/liquidity amplifying price swings. The $400M market cap and negative cash flow create significant event risk around capital raises and regulatory decisions. Estimated beta likely exceeds 1.5-2.0x relative to broader market given biotech sector characteristics and company-specific execution risks.
